These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 33233865)

  • 1. Regulation of Glutamatergic Activity via Bidirectional Activation of Two Select Receptors as a Novel Approach in Antipsychotic Drug Discovery.
    Cieślik P; Wierońska JM
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous activation of muscarinic and GABA
    Cieślik P; Woźniak M; Tokarski K; Kusek M; Pilc A; Płoska A; Radulska A; Pelikant-Małecka I; Żołnowska B; Sławiński J; Kalinowski L; Wierońska JM
    Behav Brain Res; 2019 Feb; 359():671-685. PubMed ID: 30267715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutual activation of glutamatergic mGlu
    Cieślik P; Woźniak M; Rook JM; Tantawy MN; Conn PJ; Acher F; Tokarski K; Kusek M; Pilc A; Wierońska JM
    Psychopharmacology (Berl); 2018 Oct; 235(10):2897-2913. PubMed ID: 30054675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mGlu₅-GABAB interplay in animal models of positive, negative and cognitive symptoms of schizophrenia.
    Wierońska JM; Kłeczek N; Woźniak M; Gruca P; Łasoń-Tyburkiewicz M; Papp M; Brański P; Burnat G; Pilc A
    Neurochem Int; 2015 Sep; 88():97-109. PubMed ID: 25863284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of GABAB Receptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu4 Receptor, LSP4-2022.
    Woźniak M; Acher F; Marciniak M; Lasoń-Tyburkiewicz M; Gruca P; Papp M; Pilc A; Wierońska JM
    Curr Neuropharmacol; 2016; 14(5):413-26. PubMed ID: 26769224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting glutamate synapses in schizophrenia.
    Field JR; Walker AG; Conn PJ
    Trends Mol Med; 2011 Dec; 17(12):689-98. PubMed ID: 21955406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation.
    Gray L; van den Buuse M; Scarr E; Dean B; Hannan AJ
    Int J Neuropsychopharmacol; 2009 Feb; 12(1):45-60. PubMed ID: 18593507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting of metabotropic glutamate receptors for the treatment of schizophrenia.
    Chaki S; Hikichi H
    Curr Pharm Des; 2011; 17(2):94-102. PubMed ID: 21355835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabotropic glutamate receptors as targets for new antipsychotic drugs: Historical perspective and critical comparative assessment.
    Wierońska JM; Zorn SH; Doller D; Pilc A
    Pharmacol Ther; 2016 Jan; 157():10-27. PubMed ID: 26549541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of group I metabotropic glutamate receptors in schizophrenia.
    Pietraszek M; Nagel J; Gravius A; Schäfer D; Danysz W
    Amino Acids; 2007 Feb; 32(2):173-8. PubMed ID: 16699816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of MK-801-Induced Disruptions in Social Interactions and Working Memory with Simultaneous Administration of LY487379 and VU152100 in Mice.
    Cieślik P; Radulska A; Pelikant-Małecka I; Płoska A; Kalinowski L; Wierońska JM
    Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31174329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions.
    Bolbecker AR; Shekhar A
    Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schizophrenia: moving beyond monoamine antagonists.
    Conn PJ; Tamminga C; Schoepp DD; Lindsley C
    Mol Interv; 2008 Apr; 8(2):99-107. PubMed ID: 18403654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Targeting metabotropic glutamate receptors to develop novel antipsychotics].
    Chaki S; Yoshida S; Okuyama S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):207-13. PubMed ID: 21226317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Review on Emerging Drug Targets in Treatment of Schizophrenia.
    Ved HS; Doshi GM
    Curr Drug Targets; 2020; 21(15):1593-1605. PubMed ID: 32538726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Muscarinic receptors as a target for drugs treating schizophrenia.
    Bymaster FP; Felder C; Ahmed S; McKinzie D
    Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):163-81. PubMed ID: 12769625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia.
    Stansley BJ; Conn PJ
    Curr Opin Pharmacol; 2018 Feb; 38():31-36. PubMed ID: 29486374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor mechanisms in the treatment of schizophrenia.
    Reynolds GP
    J Psychopharmacol; 2004 Sep; 18(3):340-5. PubMed ID: 15358977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent patents on positive allosteric modulators of the metabotropic glutamate 5 receptor as a potential treatment for schizophrenia.
    Kanuma K; Aoki T; Shimazaki Y
    Recent Pat CNS Drug Discov; 2010 Jan; 5(1):23-34. PubMed ID: 19832691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.
    Chavez-Noriega LE; Schaffhauser H; Campbell UC
    Curr Drug Targets CNS Neurol Disord; 2002 Jun; 1(3):261-81. PubMed ID: 12769619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.